Navigation Links
Free 2D/3D Advanced Visualization Software for CT and MRI Now Available From FiatLux Imaging
Date:11/3/2009

REDMOND, Wash., Nov. 3 /PRNewswire/ -- Medical software company FiatLux Imaging, Inc., located in Redmond, WA, announces the availability of FiatLux Visualize(TM) Free, advanced 2D/3D visualization software for CT and MRI imaging data. The free software is available for any healthcare professional via download from www.FiatLuxImaging.com. There is no charge for download or use.

"There is tremendous unrealized potential in medical imaging data," stated Quentin Dewolf, CEO of FiatLux Imaging.

"CT and MRI scanners generate huge amounts of data every day, yet the vast majority of that data is never seen outside of the radiology suite. If it were, we believe referring physicians could make better decisions, patients could gain insight into their conditions, and the expense and inconvenience of duplicate scans could be avoided.

We deliver advanced visualization to any healthcare professional, not just the small number of radiologists using expensive software on high-end workstations."

FiatLux Visualize Free is the only free advanced visualization software for CT and MRI imaging data that runs on virtually any modern Windows PC/laptop/notebook/tablet - including Windows 7 - and is cleared by the FDA for clinical use in the United States. FiatLux Visualize Free is a fully-featured 2D/3D visualization application - not a demo - for any healthcare professional needing an easy-to-use means of reformatting and viewing DICOM-compatible imaging data.

The software is useful for any healthcare professional, including specialists such as surgeons and cardiologists, primary care physicians, radiologists and radiologic technologists, physician's assistants, and clinical nurse specialists. Medical students and residents will find FiatLux Visualize Free invaluable for studying anatomy, identifying pathology, and reviewing cases.

Typical uses of FiatLux Visualize Free include an easy-to-use, 2D/3D viewe
'/>"/>

SOURCE FiatLux Imaging, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Launches Orphan Drug Workshop at KGI 2Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 1Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 2Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 3Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 4Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 5Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 1Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 2Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 3Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 4Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 5Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 6Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 7Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 8Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 9Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 10Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 11Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 12Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 13Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 14Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 15Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 16Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 17Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 18Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 19Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 20Geneticists hunt for scleroderma triggers 60340 1Geneticists hunt for scleroderma triggers 60340 2